Discovery of anti-Formin-like 1 protein (FMNL1) antibodies in membranous nephropathy and other glomerular diseases August 11, 2022 READ MORE
Nimble Therapeutics Announces Achievement of Development Milestones from Multiple Partnered Programs Connected to a Strategic Large Pharma Collaboration May 17, 2022 READ MORE
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody December 23, 2021 READ MORE
Nimble Therapeutics and Incyte Expand their Strategic Research Collaboration to Discover Additional Novel Peptide Therapeutics September 14, 2021 READ MORE
Nimble Therapeutics Appoints Cyrus Arman, PhD, MBA as Chief Business Officer September 8, 2021 READ MORE
Nimble Therapeutics and RayzeBio Announce Strategic Research Collaboration to Discover & Develop Novel Peptide-Based Radiopharmaceuticals June 28, 2021 READ MORE
